Managing Side Effects of Anti-VEGF Bevacizumab & Anti-EGFR Cetuximab and Panitumumab

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Pashtoon Kasi from City of Hope to discuss the management of side effects associated with key treatments utilized in colorectal cancer, but also in other tumor types. 

We dived deep into two important drug classes: Bevacizumab, an anti-VEGF antibody, and the anti-EGFR antibodies, Panitumumab and Cetuximab. Dr. Kasi provided a comprehensive overview of these targeted therapies, their mechanisms of action, and the common side effects that patients may experience.

Key topics covered in this episode included:
•⁠  ⁠Overview of Bevacizumab and its side effects, including hypertension, proteinuria, and risk of bleeding.
•⁠  ⁠Clinical pearls for managing side effects associated with Bevacizumab.
•⁠  ⁠Discussion on the skin toxicities, nail changes, and electrolyte imbalances related to Panitumumab and Cetuximab.
•⁠  ⁠The importance of preemptive strategies in managing skin rashes and other side effects.
•⁠  ⁠Insights into infusion reactions with Cetuximab and considerations for patient safety.

Join us for this informative discussion that aims to enhance your understanding of these critical therapies and improve patient outcomes. 

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

Don't forget to check out our other episodes in the Tox Check series, where we explore antibody-drug conjugates and CAR T therapies.
Subscribe to our channel for more insights on oncology treatments and patient care!